These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 24043137

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Famitinib in metastatic renal cell carcinoma: a single center study.
    Zhang W, Zhou AP, Qin Q, Chang CX, Jiang HY, Ma JH, Wang JW.
    Chin Med J (Engl); 2013 Nov; 126(22):4277-81. PubMed ID: 24238512
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Jun; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 8. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y.
    J Hematol Oncol; 2016 Oct 04; 9(1):105. PubMed ID: 27716285
    [Abstract] [Full Text] [Related]

  • 9. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 10. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
    Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E.
    J Clin Oncol; 2006 Jan 01; 24(1):25-35. PubMed ID: 16314617
    [Abstract] [Full Text] [Related]

  • 11. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(2):165-74. PubMed ID: 16736151
    [Abstract] [Full Text] [Related]

  • 12. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.
    Cancer Med; 2016 Jul 01; 5(7):1416-24. PubMed ID: 27109549
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
    J Clin Oncol; 2008 Aug 01; 26(22):3743-8. PubMed ID: 18669461
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW.
    Cancer Chemother Pharmacol; 2016 Jun 01; 77(6):1193-200. PubMed ID: 27103123
    [Abstract] [Full Text] [Related]

  • 15. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A.
    Clin Cancer Res; 2002 Sep 01; 8(9):2798-805. PubMed ID: 12231519
    [Abstract] [Full Text] [Related]

  • 16. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 01; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
    Clin Cancer Res; 2004 Sep 01; 10(17):5732-40. PubMed ID: 15355900
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M, He CS, Huang JK, Lin QZ.
    Eur J Cancer; 2015 Mar 01; 51(5):595-603. PubMed ID: 25618828
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 20. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
    Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C.
    Oncologist; 2019 Apr 01; 24(4):455-e121. PubMed ID: 30478190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.